Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
Check source scope before reading a dose
Renal Drug Handbook, 5th edition - Losartan potassium
Product / population
Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Renal method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
Source revision
5th edition; 2019 copyright; historical reference
Retrieved
2026-09-05
Local review status
Historical handbook cross-check; not a current U.S. protocol
Handbook
Renal Drug Handbook, 5th edition - Losartan potassium
UK Renal Pharmacy Group / CRC Press · Historical adult renal/RRT summary. U.S. product identity anchored to the separate locally included DailyMed label. This is not a current U.S. product label.
Renal method: Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR. Source date: 5th edition; 2019 copyright; historical reference Retrieved: 2026-09-05
Historical handbook cross-check; not a current U.S. protocol
Historical renal / replacement-therapy guidance
At 20-50 mL/min, retain the usual indication dose. At 10-20 and <10, the book recommends an initial 25 mg dose and response-based titration. PD/HD/high-flux use the <10 band; continuous therapy uses 10-20; the drug is described as not dialyzed. This conservative low-function starting approach is distinct from the U.S. label, which ties lower starting doses especially to volume depletion. Monitor potassium and renal function.
HB30-losartan-1 · Source locator: Printed page 611: renal impairment, RRT and other information
Source-specific limits
Separate source recommendation, not proof of agreement or contemporary clinical validation. Dialysis predictions are retained with their original certainty.
Source identity and provenance
Retrieved
2026-09-05
Handbook page
5th edition, printed p. 611; uploaded PDF p. 630
Renal-function method
Book table headed GFR (mL/min); its preface states renal adjustments generally derive from Cockcroft-Gault CrCl. Do not silently relabel as indexed eGFR.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.